You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.
At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.
Parnell Pharmaceuticals delisting from Nasdaq
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021
Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective
Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective
Australia-based Parnell Pharmaceuticals Holdings Ltd. will delist from the Nasdaq, effective Dec. 31.
The company said it believes that there has been an incongruence between the potential realizable value of Parnell's underlying assets and its share price as a Nasdaq-listed company, according to a news release.
The veterinarian pharmaceutical company anticipates its shares to be quoted on the OTC Pink open market following the delisting.